Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization
B Lu, WF Dai, R Croxford, W Isaranuwatchai… - Cancer …, 2023 - Wiley Online Library
Background The efficacy‐effectiveness gap between randomized trial and real‐world
evidence regarding the clinical benefit of ipilimumab for metastatic melanoma (MM) has …
evidence regarding the clinical benefit of ipilimumab for metastatic melanoma (MM) has …
Anticoagulant use and associated outcomes in older patients receiving home palliative care: a retrospective cohort study
N Chin-Yee, T Gomes, P Tanuseputro, R Talarico… - Cmaj, 2022 - Can Med Assoc
Background: The benefits and harms of anticoagulants for people near the end of life are not
well understood, nor is it known what proportion of patients discontinue these medications …
well understood, nor is it known what proportion of patients discontinue these medications …
[HTML][HTML] Is it time to commit to a process to re-evaluate oncology drugs? A descriptive analysis of systemic therapies for solid tumour indications reviewed in Canada …
S Sehdev, A Chambers - Current Oncology, 2022 - mdpi.com
We undertook an analysis of the Canadian Agency for Drugs and Technologies in Health
(CADTH)'s health technology assessments (HTAs) of systemic therapies for solid tumour …
(CADTH)'s health technology assessments (HTAs) of systemic therapies for solid tumour …
Anticoagulant use in older patients receiving home palliative care: a retrospective cohort study
N Chin-Yee - 2022 - search.proquest.com
Objective: To describe the prevalence of anticoagulant use and identify predictive factors for
anticoagulant discontinuation among home palliative care recipients in Ontario …
anticoagulant discontinuation among home palliative care recipients in Ontario …